Intersect ENT (XENT) Tops Q4 EPS by 10c, Revenues Beat; Affirms FY20 Revenue Guidance Below Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Intersect ENT (XENT) Tops Q4 EPS by 10c, Revenues Beat; Affirms FY20 Revenue Guidance Below Consensus

Intersect ENT Reports Fourth Quarter and Full Year 2019 Results

February 24, 2020 7:00 AM EST

MENLO PARK, Calif.--(BUSINESS WIRE)-- Intersect ENT, Inc. (NASDAQ: XENT), a company transforming care for patients with ear, nose and throat (ENT) conditions, today reported financial results for the fourth quarter and full year ended December 31, 2019.

2019 was a year of change for Intersect ENT. New company leadership brought a renewed focus to the Companys commercial activities, with particular attention to market development and clinical selling. In addition, further investment was made in the go-to-market infrastructure for SINUVA® aimed at reducing market access barriers that limit physicians ability and willingness to procure and... More